<DOC>
	<DOCNO>NCT01324830</DOCNO>
	<brief_summary>The aim Phase Ia ( dose escalation ) part trial ass MTD BI 847325 administer escalate dos 2 treatment arm . In Phase Ib expansion part trial , aim evaluate safety profile BI 847325 recommend dose schedule ass target modulation potential antitumour efficacy patient select tumour type .</brief_summary>
	<brief_title>Monotherapy Dose Finding With BI 847325 Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Patients histologically cytologically confirm diagnosis advance unresectable and/or metastatic solid tumour , fail conventional treatment therapy proven efficacy exists amenable standard therapy . 2 . Age 18 year old 3 . Written inform consent consistent ICHGCP local legislation 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 5 . Recovery therapyrelated toxicity previous antitumour therapy Common Terminology Criteria Adverse Events ( CTCAE ) = grade 1 ( exception alopecia ) . 6 . Written inform consent use archival tumour sample determination BRAF/RAS mutational status . 7 . Life expectancy least 12 week . 8 . In escalation phase , PK close predict Cmax sign PD modulation present , optional tumour biopsy ( timepoints expansion phase ) patient consent . In addition , patient include expansion phase ( part Ib ) must : 9. diagnose one follow tumour : melanoma , colorectal carcinoma , Non Small Cell Lung Cancer ( NSCLC ) exocrine pancreas adenocarcinoma , show archival tumour sample KRAS BRAF mutation . 10. measurable disease . 11. documented/proven progressive disease within last 6 month , accord Response Evaluation Criteria In Solid Tumours ( RECIST ) criteria 11. tumour lesion accessible biopsy ( pre posttreatment ) : mandatory patient colorectal carcinoma melanoma , optional patient NSCLC exocrine pancreas adenocarcinoma . Exclusion criterion : 1 . Inability swallow tablet . 2 . Additional serious illness , concomitant nononcological disease ( e.g . active infectious disease know chronic Hepatitis B/Hepatitis C infection HIV ) , ongoing toxicity prior therapy consider investigator potentially compromise patient 's safety trial . 3 . Clinical evidence symptomatic progressive brain leptomeningeal disease last 28 day . 4 . Second malignancy currently require another anticancer therapy . 5 . Absolute neutrophil count less 1500/mm3 . 6 . Platelet count less 100 000/mm3 . 7 . Bilirubin great 1.5 mg/dL ( &gt; 26 µmol/L , SI unit equivalent ) ( except know Gilbert 's syndrome ) . 8 . Aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( related liver metastasis , great five time upper limit normal ) . 9 . Serum creatinine great 1.5 mg/dL ( &gt; 132 µmol/L , SI unit equivalent ) . 10 . Previous episode QT prolongation due medication , result , discontinue ; long QT syndrome ; QTc Fridericia 's correction &gt; 480 msec screen ECG . 11 . Pregnancy breastfeed . 12 . Women men sexually active unwilling use medically acceptable method contraception . 13 . Treatment investigational drug participation another clinical interventional trial within past four week start therapy concomitant trial . 14 . Systemic anticancer therapy radiotherapy within past four week start therapy concomitantly trial . This restriction apply LHRH agonist , steroid bisphosphonates . 15 . Patients unable comply protocol . 16 . Active alcohol drug abuse . 17. history presence cardiovascular abnormality deem clinically relevant investigator . Myocardial infarction within 6 month prior study . 18 . Cardiac leave ventricular ejection fraction &lt; 50 % le institutional low limit normal MUGA echocardiography</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>